RALEIGH-DURHAM, N.C., Aug. 15, 2016 /PRNewswire/ -- Kineticos, in partnership with Ipsos Healthcare and Demy-Colton, today announced the Q2 2016 results of the Biopharma CEO Confidence Index, a forward-looking indicator designed to measure C-suite sentiment and confidence in the Biopharma industry's economy.
51 biopharma CEOs were surveyed in the Q2 study and the data indicates CEO confidence remained stable after leveling off in Q1. Here are a few highlights from the Q2 2016 Biopharma CEO Confidence Index:
- CEOs who were very confident in their ability to raise capital in the public market, rose from 18% in Q1 to 39% in Q2
- Deal values and deal competition remained stable while those labeling the overall deal landscape as good declined for a third straight quarter (45% in Q1 to 35% in Q2)
- Confidence in delivering clinically differentiated assets remains high (65%)
- Confidence in the regulatory environment is growing stronger as 31% were very confident in Q2, an increase of 9% from Q1
- CEOs planning to partner externally decreases (70% to 65%), remains significantly higher than those planning to commercialize independently (12%)
- 57% of CEOs indicated that the largest risk to their business is capital stability, followed by clinical results at 14%
A more extensive summary and analysis of the Q2 2016 Biopharma CEO Confidence Index is available at www.BiopharmaCEOConfidenceIndex.com.
When asked about the Q2 results, Steve Girling, President of Ipsos Healthcare said, "After a year of surveying Biotech CEOs who are leading development stage companies, we've found that early exuberance about the flow of available funds has been replaced by a broader confidence in the potential to bring new assets to market." Girling went on to say, "The upcoming US election is likely to have a material impact on the industry, so it will be fascinating to see whether, and how quickly this influences CEO confidence."
Shailesh Maingi, CEO and founder of Kineticos commented on the 1-year milestone as well. "The Q2 survey marks one full year of results for the Biopharma CEO Confidence Index. I want to thank our partners for their support and all the CEOs who have participated." Referring to the Q2 results, Maingi added, "It is clear that we are setting a new, lower baseline for overall confidence and the 6 individual parameters we measure. We can also see a correlation with our results and behavior of CEOs. The increased difficulty of raising capital through public markets has forced Biopharma CEOs to rely more on co-development and partnership agreements. In that regard, the index has become a leading indicator of Biopharma strategy and tactics."
About the Biopharma CEO Confidence Index
The Biopharma CEO Confidence Index is the first and only forward-looking indicator designed to measure C-suite sentiment and confidence in the biopharma industry's economy. This confidence—or lack thereof—is defined by the degree of optimism within six key business indicators, including:
- Capital Markets
- Deal Landscape
- Clinical Development
- Regulatory Affairs
- Business Model and Workforce
Measuring confidence through these indicators over time will demonstrate an ebb and flow of market dynamics and confidence in the future success of companies and growth in the overall market.
Kineticos is a specialized management consulting firm serving the life science industry.
The firm is focused on identifying opportunities to drive strategic growth and achieve operational excellence for its clients. Through its practice areas, the firm has experience working with companies across the life science industry ecosystem. For more information on Kineticos and its capabilities, please visit www.kineticos.com.
About Ipsos Healthcare
Ipsos Healthcare is a fact-based research, consulting and strategy specialist in the global biopharmaceutical industry. For more information, please visit www.ipsos.com/marketing/healthcare.
Demy-Colton produces highly specialized investor and business conferences exclusively for the biopharmaceutical and life sciences industry. For more information, please visit www.demy-colton.com.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/overall-confidence-remains-strong-in-the-q2-biopharma-ceo-confidence-index-300313512.html